Full Press Release Details
Powered and protected by
Privacy
XERS Positive Sentiment Score: 70/100
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
Key Takeaway: Xeris Biopharma has announced that it received a notice of allowance from the U.S. Patent and Trademark Office for a new patent covering KEVEYIS®. This patent is expected to strengthen the company's intellectual property portfolio and could enhance its competitive edge in the market.
Market Sentiment Analysis
POSITIVE FACTORS
- Xeris Biopharma received a notice of allowance for a new patent.
- The patent covers KEVEYIS®, enhancing its market position.
- This development could lead to increased revenue opportunities.
Frequently Asked Questions
What patent was allowed for Xeris Biopharma?
The U.S. Patent and Trademark Office allowed a new patent covering KEVEYIS®.
How does the new patent benefit Xeris Biopharma?
The patent strengthens Xeris Biopharma's intellectual property and market position.
What is KEVEYIS®?
KEVEYIS® is a product developed by Xeris Biopharma, now under new patent protection.
What does a notice of allowance mean?
A notice of allowance indicates that the patent application is approved for grant.